Clinical trials: UTUC, open to volunteers
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Urothelial Carcinoma, Urothelial Carcinoma Recurrent
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- uTRACT (NCT05874921)
- Testing
- Jelmyto (mitomycin) for pyelocalyceal solution
- Where
- 22 sites in United States
- Volunteers
- 450 people
- Sponsor
- UroGen Pharma Ltd.
Ureter Cancer, Renal Pelvic Carcinoma
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
This is a prospective cohort study to analyse the safety and efficacy of postoperative adjuvant radiotherapy combined with immunotherapy versus surgery alone group of UTUC patients with T3-4 stages or lymph nodes metastasis(N+)…
- Conditions
- Ureter Cancer, Renal Pelvic Carcinoma, Advanced Urothelial Carcinoma
- Trial name
- NCT06598761
- Testing
- Immunotherapy+radiotherapy, surveillance alone
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Upper Tract Urothelial Cancer
Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients
To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery
- Trial name
- NCT06987552
- Testing
- Da Vinci SP Surgical System
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Taiwan University Hospital
Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
This study is designed as an open-label, single-arm, single center, phase II clinical trial, aiming to evaluate the efficacy of neoadjuvant Tislelizumab combined with Nab-Paclitaxel for patients with non-metastatic upper tract…
- Conditions
- Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
- Trial name
- NCT07126119
- Testing
- Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
Carcinoma, Upper Tract Urothelial Carcinoma
A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.
- Conditions
- Carcinoma, Upper Tract Urothelial Carcinoma, UTUC
- Trial name
- 1 (NCT05917158)
- Testing
- RC48-ADC and JS001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jinling Hospital, China
UTUC
POST URS Chemotherapy Instillation
The goal of this study is to evaluate the safety and oncological outcomes of single chemotherapy bladder instillation following endoscopic treatment for UTUC in UTUC suspected patients .The main aim is to determine the efficacy…
- Trial name
- NCT06167057
- Testing
- Mitomycin/Gemcitabine, Saline
- Where
- 10 sites in Israel
- Volunteers
- 264 people
- Sponsor
- Carmel Medical Center
Upper Tract Urothelial Carcinoma
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for…
- Trial name
- NCT06798246
- Testing
- Chemotherapy, Immunotherapy, ADC
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Bladder Cancer, Bladder Urothelial Carcinoma
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it.
- Trial name
- NAUTICAL (NCT04574960)
- Testing
- Gemcitabine, Cisplatin, Carboplatin
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Upper Urinary Tract Urothelial Carcinoma
HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC
This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU)…
- Trial name
- HERO-UTUC (NCT07591805)
- Testing
- Drug: Disitamab Vedotin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- RenJi Hospital
High-risk Muscle Invasive Urothelial Carcinoma
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection.
- Trial name
- TU-04 (NCT07720284)
- Testing
- Dato-DXd, Rilvegostomig, Durvalumab
- Where
- 160 sites in United States, Australia and 14 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Low Grade Upper Tract Urothelial Carcinoma
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
- Trial name
- SURF303 (NCT07265947)
- Testing
- Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 285 people
- Sponsor
- Tyra Biosciences, Inc
Upper Tract Urothelial Cancer
A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)
There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical…
- Trial name
- NCT05438537
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Chinese University of Hong Kong
Upper Tract Urothelial Carcinoma
OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma
Upper tract urothelial carcinoma (UTUC) is difficult to stage accurately because cross-sectional imaging and ureteroscopic biopsy may not reliably demonstrate muscular or periureteral invasion.
- Trial name
- NCT07751796
- Testing
- OptiCross HD Coronary Imaging Catheter
- Volunteers
- 15 people
- Sponsor
- Yonsei University
Upper Tract Urothelial Carcinoma
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
This randomized, open-label, multicenter phase III study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial…
- Trial name
- LUXUS41 (NCT07498907)
- Testing
- Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2)
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Peking University First Hospital
Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer
Single-Dose Intravesical Chemotherapy After Diagnostic URS
Study design This study is a Phase III, randomized, open-label, multi-center, global study to determine the efficacy of a single immediate intravesical chemotherapy instillation (SI) in the prophylaxis of intravesical recurrence…
- Trial name
- MINERVA (NCT05810623)
- Testing
- Intravesical Solution
- Where
- 2 sites in Austria
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- David D'Andrea
Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients .
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
- Trial name
- NCT05912816
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Urothelial Carcinoma
Liquid Biospy for Urinary Cancers
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and…
- Trial name
- CIRCE (NCT06116396)
- Testing
- Genetic analysis on isolated cells
- Where
- Italy
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC).
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
- Trial name
- NCT07614594
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Henan Provincial People's Hospital
Low-grade Upper Tract Urothelial Carcinoma
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects.
- Trial name
- LUNAR (NCT06668493)
- Testing
- Nadofaragene Firadenovec
- Where
- 9 sites in United States, France
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals